1. Pipeline & HCV
UK-CAB 31 January 2009

2. Pipeline TMC435 Hepatitis C RSV353 (Respiratory Syncitial Virus)
Phase II-a, small cohorts, cohort 5. EASL
Phase II-b later in 2009
RSV353 (Respiratory Syncitial Virus)
Phase I

3. Hepatitis C: Telaprevir.
Co-development with VERTEX.
Sponsored and managed by Vertex
1050 Treatment-naïve patients.
Sponsored and managed by TIBOTEC
650 Treatment-failure patients

4. Studies for HIV/HCV coinfected patients
DDI studies ongoing. Tenofovir: no significant interaction
Coinfection study: pilot study will start this year
Synopsis of protocol has been sent to ECAB for review
US Community has seen and commented